קו-דיובאן 16012.5 מג טבליות מצופות Israel - hebreiska - Ministry of Health

קו-דיובאן 16012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

קו-דיובאן 16025 מג טבליות מצופות Israel - hebreiska - Ministry of Health

קו-דיובאן 16025 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

דיפרוספאן זריקה Israel - hebreiska - Ministry of Health

דיפרוספאן זריקה

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

אלימטה 500 מג Israel - hebreiska - Ministry of Health

אלימטה 500 מג

eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

אלימטה 500 מג Israel - hebreiska - Ministry of Health

אלימטה 500 מג

eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

אלימטה Israel - hebreiska - Ministry of Health

אלימטה

eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 100 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

ונטולין זריקות Israel - hebreiska - Ministry of Health

ונטולין זריקות

glaxo smith kline (israel) ltd - salbutamol as sulfate - תמיסה להזרקה - salbutamol as sulfate 0.5 mg/ml - salbutamol - salbutamol - for relief of severe bronchospasm associated with asthma and bronchitis status asthmaticus.

סופלנה Israel - hebreiska - Ministry of Health

סופלנה

abbott medical laboratories ltd - ascorbic acid 41.50 mg; biotin 70.10 mcg - liquid - other combinations of nutrients - specialized liquid nutrition for patients requiring protein, electrolyte and fluid restrictions. suplena is a high calorie low nitrogen, low electrolyte liquid food. in the dietary management of patients prone to uremia.

אוסמולייט HN Israel - hebreiska - Ministry of Health

אוסמולייט hn

abbott medical laboratories ltd - ascorbic acid 65 mg / 100 ml; biotin 57.6 mcg / 100 ml - liquid - fat/carbohydrates/proteins/minerals/vitamins, combinations - ready to use, high - nitrogen isotonic liquid nutrition.

איקטיבנט טבע Israel - hebreiska - Ministry of Health

איקטיבנט טבע

teva israel ltd - icatibant as acetate - תמיסה להזרקה - icatibant as acetate 30 mg / 3 ml - icatibant